Neumora Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

NMRA$0.50+3.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements (Unaudited)Condensed Consolidated Balance Sheets

Condensed Cons olidated Balance Sheets

(in thousands)

	June 30,2024	December 31,2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$150,678	$374,038
Short-term marketable securities	220,961	79,944
Prepaid expenses and other current assets	26,680	24,297
Total current assets	398,319	478,279
Long-term marketable securities	—	9,845
Property and equipment, net	1,476	1,790
Operating lease right-of-use assets	3,465	5,068
Restricted cash	1,213	1,213
Total assets	$404,473	$496,195
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,082	$337
Accrued liabilities	18,303	21,257
Early exercise liability, current portion	133	139
Operating lease liabilities, current portion	3,607	3,378
Total current liabilities	23,125	25,111
Operating lease liabilities, net of current portion	—	1,853
Early exercise liability, net of current portion	89	155
Total liabilities	23,214	27,119
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock	16	16
Additional paid-in capital	1,197,285	1,172,570
Accumulated other comprehensive loss	(187)	(76)
Accumulated deficit	(815,855)	(703,434)
Total stockholders’ equity	381,259	469,076
Total liabilities and stockholders’ equity	$404,473	$496,195

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.